Abstract
Ten years ago M. Kazatchkine, U. Nydegger, and Y. Sultan decided to treat patients with acquired hemophilia using intravenous immunoglobulins (IVIg). This was during a meeting in Denmark about autoimmune diseases and IVIg. In 1983, several authors had reported on the efficacy of IVIg in autoimmune diseases such as idiopathic thrombocytopenic purpura in children1,2 and adults,3 immune neutropenia,2,4 and red cell aplasia.5 Autoantibodies to factor VIII (F.VIII) occurring in either otherwise healthy patients or during the course of a more characterized immune disorder such as disseminated lupus erythematosus (DUE) and rheumatoid polyarthritis seemed to be good models. One major reason is that the neutralizing capacity of autoantibodies to F.VIII is easily and reproducibly quantified using the Bethesda assay, while this is not the case in most of the autoimmune diseases mentioned above.
Keywords
- Factor Viii
- Idiopathic Thrombocytopenic Purpura
- Inhibitor Titer
- Factor Viii Inhibitor
- High Dose Intravenous Immunoglobulin
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
P. Imbach, S. Barandun, V. d’Apuzzo et al.. High dose intravenous gammaglobulin, for idiopathic thrombocytopenic purpura in childhood. Lancet i: 1228 (1981).
J.B. Bussel, R.P. Kimberly, R.D. Inman et al.. Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. Blood 62: 480 (1983).
R.E. Schmidt, U. Budde, G. Schafer et al. High dose intravenous immunoglobulin for idiopathic thrombocytopenic purpura. Lancet ii: 475 (1981).
S. Pollack, C. Cunningham-Rundles, E.M. Smithwick, S. Barandun, R.A. Good, High dose intravenous gammaglobulin for autoimmune neutropenia, N Engl J Med 307: 243 (1982).
JP. Clauvel, W. Vainchenker, A. Herrera et al.. Treatment of pure red cell aplasia by high dose intravenous immunoglobulins, Br J Haematol 55: 380 (1983).
Y. Sultan, M.D. Kazatchkine, P. Maisonneuve, U.E. Nydegger, Anti-idiotypic suppression of autoantibodies to factor VIII (anti-haemophilic factor) by high-dose intravenous gammaglobulin. Lancet ii: 765 (1984).
F. Rossi, Y. Sultan, M.D. Kazatchkine, Anti-idiotypes against autoantibodies and alloantibodies to factor VIIIC (anti-hemophilic factor) are present in therapeutic polyspecific normal immunoglobulins, Clin Exp Immunol 74: 311 (1988).
G. Borradori, A. Hirt, A. Luthy, H.P. Wagner, P. Imbach, Haemophilia due to factor VIII inhibitors in a patient suffering from an autoimmune disease. Treatment with intravenous immunoglobulin, Blut 48: 403 (1984).
R. Zimmerman, B. Kommereil, J. Herenberg, W. Eich, K. Rother, KL. Schimpf
Intravenous IgG for patients with spontaneous inhibitor to factor VIII, Lancet i:273 (1985).
D. Green, H.C. Kwaan, An acquired factor VIII inhibitor responsive to high dose gammaglobulin, Thromb Haemost 58: 1005 (1987).
L.O. Carreras, G.N. Perez, D.L. Xavier, A.N. Blanco, L.B. Penalva, Autoimmune factor VIII inhibitor responsive to gammaglobulin without in vitroneutralization, Thromb Haemost 60: 343 (1988).
Y. Sultan, F. Rossi, M.D. Kazatchkine, Recovery from anti-VIIIC (anti-hemophilic factor) autoimmune disease is dependent on generation of anti-idiotypes against anti-FVIHc autoantibodies, Proc Natl Acad Sci USA 84: 828 (1987).
C. Tiarks, L. Pechet, RE. Humphreys, Development of anti-idiotypic antibodies in a patient with a factor VIII autoantibody. Am J Hematol 32: 217 (1989).
M. Algiman, G. Dietrich, U.E. Nydegger, D. Boyeldieu, Y. Sultan, M.D. Kazatchkine, Antibodies to factor VIII (anti-hemophilic factor) in healthy individuals, Proc Natl Acad Sci USA 89: 3795 (1992).
G. Dietrich, M. Algiman, Y. Sultan, U.E. Nydegger, M.D. Kazatchkine, Origin of anti-idiotypic activity against anti-factor VIII autoantibodies in pools of normal human immunoglobulin G (IVIg), Blood 79, 11: 2946 (1992).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Plenum Press, New York
About this chapter
Cite this chapter
Sultan, Y., Nydegger, U., Kazatchkine, M.D., Rossi, F., Algiman, M., Dietrich, G. (1995). IVIg in the treatment of patients with factor VIII inhibitors. In: Aledort, L.M., Hoyer, L.W., Lusher, J.M., Reisner, H.M., White, G.C. (eds) Inhibitors to Coagulation Factors. Advances in Experimental Medicine and Biology, vol 386. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0331-2_17
Download citation
DOI: https://doi.org/10.1007/978-1-4613-0331-2_17
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-8001-6
Online ISBN: 978-1-4613-0331-2
eBook Packages: Springer Book Archive